Registry for Adults With Plasma Cell Disorders (PCD's)

Launched by UNC LINEBERGER COMPREHENSIVE CANCER CENTER · Oct 22, 2018

Keywords

ClinConnect Summary

This clinical trial is focused on creating a registry for adults who have plasma cell disorders (PCDs), which are conditions like multiple myeloma, amyloidosis, and several others that affect the plasma cells in the body. The goal is to gather important health information from patients who agree to participate, including completing an assessment about their overall health. This information will help improve future research on these disorders and how they affect patients. Participants will also have the option to provide a blood sample to look for a specific genetic marker related to aging.

To be eligible for this study, you must be at least 18 years old and have a confirmed diagnosis of a plasma cell disorder. You will need to be receiving treatment at UNC Cancer Hospitals or affiliated clinics. Participants should be able to read and speak English, and they must agree to take part in the study and complete the necessary assessments. There are no special tests required to join, and the study aims to evaluate how patients respond to participating in this type of research. If you're interested, this could be a great opportunity to contribute to valuable findings that may help others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients have an outpatient appointment or are hospitalized inpatient at UNC Cancer Hospitals, or affiliated clinic settings or participating sites for the evaluation and management of a PCD.
• • Patients have a documented diagnosis of PCD defined as the presence of a monoclonal protein and/or monoclonal plasma cell population. Examples of PCDs include but are not limited to monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple (active) myeloma; plasma cell leukemia; Castleman's disease; amyloidosis; light and/or heavy chain deposition disease; Polyneuropathy, Organomegaly, Endocrinopathy,Monoclonal gammopathy and Skin changes (POEMS) syndrome; and cryoglobulinemia.
• • Age ≥18 years.
• • Must consent to participation in this study and agree to complete the assessment at baseline and follow-up time points.
• • Must be able to read and speak English.
• Exclusion Criteria:
• • Physical or psychiatric/behavioral illnesses or problems that the treating clinician feels would preclude successful participation in the study.
• • There are no imaging or lab studies required to determine eligibility.